Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset

Neurobiology of Aging

Volumn 36, Issue 1, 2015, Pages 228-240

  Dionísio, Pedro A ^a   Amaral, Joana D ^a   Ribeiro, Maria F ^a   Lo, Adrian C ^b   D'Hooge, Rudi ^b   Rodrigues, Cecília M P ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Amyloid precursor protein; Amyloid ; APP PS1 mice; Gliosis; Glycogen synthase kinase ; Tau; TUDCA

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PRESENILIN 1; PROTEIN KINASE B; TAU PROTEIN; TAUROURSODEOXYCHOLIC ACID; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CHOLAGOGUE; CYTOKINE; GLYCOGEN SYNTHASE KINASE 3 BETA; MAPT PROTEIN, MOUSE; NEUROPROTECTIVE AGENT; PRESENILIN 1, MOUSE; TAUROCHENODEOXYCHOLIC ACID;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SCREENING; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GLIA; MALE; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS INHIBITION; TRANSGENIC MOUSE; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEIN AGGREGATION, PATHOLOGICAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CHOLAGOGUES AND CHOLERETICS; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GLYCOGEN SYNTHASE KINASE 3; INFLAMMATION MEDIATORS; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; PRESENILIN-1; PROTEIN AGGREGATION, PATHOLOGICAL; RNA, MESSENGER; TAU PROTEINS; TAUROCHENODEOXYCHOLIC ACID;

EID: 84920453379     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.08.034     Document Type: Article

References (64)

1. Aplin A.E., Gibb G.M., Jacobsen J.S., Gallo J.M., Anderton B.H. Invitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J.Neurochem. 1996, 67:699-707.
2. Beaulieu J.M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49:327-347.
3. Ben Mosbah I., Alfany-Fernandez I., Martel C., Zaouali M.A., Bintanel-Morcillo M., Rimola A., Rodés J., Brenner C., Roselló-Catafau J., Peralta C. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death Dis. 2010, 1:e52.
4. Beurel E., Jope R.S. Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes. Neuroscience 2010, 169:1063-1070.
5. Born H.A., Kim J.Y., Savjani R.R., Das P., Dabaghian Y.A., Guo Q., Yoo J.W., Schuler D.R., Cirrito J.R., Zheng H., Golde T.E., Noebels J.L., Jankowsky J.L. Genetic suppression of transgenic APP rescues hypersynchronous network activity in a mouse model of Alzheimer's disease. J.Neurosci. 2014, 34:3826-3840.
6. Castro-Caldas M., Carvalho A.N., Rodrigues E., Henderson C.J., Wolf C.R., Rodrigues C.M., Gama M.J. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease. Mol. Neurobiol. 2012, 46:475-486.
7. Ding Y., Qiao A., Wang Z., Goodwin J.S., Lee E.S., Block M.L., Allsbrook M., McDonald M.P., Fan G.H. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J.Neurosci. 2008, 28:11622-11634.
8. Duan W.M., Rodrigues C.M., Zhao L.R., Steer C.J., Low W.C. Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease. Cell Transpl. 2002, 11:195-205.
9. Durairajan S.S., Liu L.F., Lu J.H., Chen L.L., Yuan Q., Chung S.K., Huang L., Li X.S., Huang J.D., Li M. Berberine ameliorates beta-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model. Neurobiol. Aging 2012, 33:2903-2919.
10. Elder G.A., Gama Sosa M.A., De Gasperi R. Transgenic mouse models of Alzheimer's disease. Mt. Sinai J. Med. 2010, 77:69-81.
11. Fernandes A., Vaz A.R., Falcao A.S., Silva R.F., Brito M.A., Brites D. Glycoursodeoxycholic acid and interleukin-10 modulate the reactivity of rat cortical astrocytes to unconjugated bilirubin. J.Neuropathol. Exp. Neurol. 2007, 66:789-798.
12. Goddyn H., Leo S., Meert T., D'Hooge R. Differences in behavioural test battery performance between mice with hippocampal and cerebellar lesions. Behav. Brain Res. 2006, 173:138-147.
13. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J.Neurochem. 2005, 93:105-117.
14. Haass C., Kaether C., Thinakaran G., Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2012, 2:a006270.
15. Hefendehl J.K., Wegenast-Braun B.M., Liebig C., Eicke D., Milford D., Calhoun M.E., Kohsaka S., Eichner M., Jucker M. Long-term invivo imaging of beta-amyloid plaque appearance and growth in a mouse model of cerebral beta-amyloidosis. J.Neurosci. 2011, 31:624-629.
16. Hu Y.S., Long N., Pigino G., Brady S.T., Lazarov O. Molecular mechanisms of environmental enrichment: impairments in Akt/GSK3beta, neurotrophin-3 and CREB signaling. PLoS One 2013, 8:e64460.
17. Jia N., Han K., Kong J.J., Zhang X.M., Sha S., Ren G.R., Cao Y.P. (-)-Epigallocatechin-3-gallate alleviates spatial memory impairment in APP/PS1 mice by restoring IRS-1 signaling defects in the hippocampus. Mol. Cell Biochem. 2013, 380:211-218.
18. Joo S.S., Kang H.C., Won T.J., Lee D.I. Ursodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1 beta and nitric oxide in rat microglia. Arch. Pharm. Res. 2003, 26:1067-1073.
19. Karpova A., Sanna P.P., Behnisch T. Involvement of multiple phosphatidylinositol 3-kinase-dependent pathways in the persistence of late-phase long term potentiation expression. Neuroscience 2006, 137:833-841.
20. Keene C.D., Rodrigues C.M., Eich T., Chhabra M.S., Steer C.J., Low W.C. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10671-10676.
21. Keene C.D., Rodrigues C.M., Eich T., Linehan-Stieers C., Abt A., Kren B.T., Steer C.J., Low W.C. Abile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp. Neurol. 2001, 171:351-360.
22. Koistinaho J., Malm T., Goldsteins G. Glycogen synthase kinase-3beta: a mediator of inflammation in Alzheimer's disease?. Int. J. Alzheimers Dis. 2011, 2011:129753.
23. Kokjohn T.A., Roher A.E. Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement. 2009, 5:340-347.
24. Lee E.B., Zhang B., Liu K., Greenbaum E.A., Doms R.W., Trojanowski J.Q., Lee V.M. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition invivo. J.Cell Biol. 2005, 168:291-302.
25. Lee H.K., Kumar P., Fu Q., Rosen K.M., Querfurth H.W. The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Mol. Biol. Cell. 2009, 20:1533-1544.
26. Lee M.S., Kao S.C., Lemere C.A., Xia W., Tseng H.C., Zhou Y., Neve R., Ahlijanian M.K., Tsai L.H. APP processing is regulated by cytoplasmic phosphorylation. J.Cell Biol. 2003, 163:83-95.
27. Leroy A., Landrieu I., Huvent I., Legrand D., Codeville B., Wieruszeski J.M., Lippens G. Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E. J.Biol. Chem. 2010, 285:33435-33444.
28. Li T., Paudel H.K. Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry 2006, 45:3125-3133.
29. Lo A.C., Callaerts-Vegh Z., Nunes A.F., Rodrigues C.M., D'Hooge R. Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice. Neurobiol. Dis. 2013, 50:21-29.
30. Ly P.T., Wu Y., Zou H., Wang R., Zhou W., Kinoshita A., Zhang M., Yang Y., Cai F., Woodgett J., Song W. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J.Clin. Invest. 2013, 123:224-235.
31. Malm T.M., Iivonen H., Goldsteins G., Keksa-Goldsteine V., Ahtoniemi T., Kanninen K., Salminen A., Auriola S., Van Groen T., Tanila H., Koistinaho J. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J.Neurosci. 2007, 27:3712-3721.
32. Masliah E., Mallory M., Alford M., DeTeresa R., Hansen L.A., McKeel D.W., Morris J.C. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001, 56:127-129.
33. Meraz-Rios M.A., Toral-Rios D., Franco-Bocanegra D., Villeda-Hernandez J., Campos-Pena V. Inflammatory process in Alzheimer's disease. Front. Integr. Neurosci. 2013, 7:59.
34. Mines M.A., Beurel E., Jope R.S. Regulation of cell survival mechanisms in Alzheimer's disease by glycogen synthase kinase-3. Int. J. Alzheimers Dis. 2011, 2011:861072.
35. Nunes A.F., Amaral J.D., Lo A.C., Fonseca M.B., Viana R.J., Callaerts-Vegh Z., D'Hooge R., Rodrigues C.M. TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-beta deposition in APP/PS1 mice. Mol. Neurobiol. 2012, 45:440-454.
36. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006, 7:940-946.
37. Ramalho R.M., Borralho P.M., Castro R.E., Sola S., Steer C.J., Rodrigues C.M. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. J.Neurochem. 2006, 98:1610-1618.
38. Ramalho R.M., Nunes A.F., Dias R.B., Amaral J.D., Lo A.C., D'Hooge R., Sebastião A.M., Rodrigues C.M. Tauroursodeoxycholic acid suppresses amyloid beta-induced synaptic toxicity invitro and in APP/PS1 mice. Neurobiol. Aging 2013, 34:551-561.
39. Ramalho R.M., Ribeiro P.S., Sola S., Castro R.E., Steer C.J., Rodrigues C.M. Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J.Neurochem. 2004, 90:567-575.
40. Reitz C., Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 2014, 88:640-651.
41. Rodrigues C.M., Sola S., Nan Z., Castro R.E., Ribeiro P.S., Low W.C., Steer C.J. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6087-6092.
42. Rodrigues C.M., Spellman S.R., Sola S., Grande A.W., Linehan-Stieers C., Low W.C., Steer C.J. Neuroprotection by a bile acid in an acute stroke model in the rat. J.Cereb. Blood Flow Metab. 2002, 22:463-471.
43. Rupp N.J., Wegenast-Braun B.M., Radde R., Calhoun M.E., Jucker M. Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol Aging 2011, 32:2324.e1-2324.e6.
44. Rutten B.P., Van der Kolk N.M., Schafer S., van Zandvoort M.A., Bayer T.A., Steinbusch H.W., Schmitz C. Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am. J. Pathol. 2005, 167:161-173.
45. Ryder J., Su Y., Ni B. Akt/GSK3beta serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. Cell Signal. 2004, 16:187-200.
46. Saito T., Matsuba Y., Mihira N., Takano J., Nilsson P., Itohara S., Iwata N., Saido T.C. Single App knock-in mouse models of Alzheimer's disease. Nat. Neurosci. 2014, 17:661-663.
47. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
48. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
49. Sereno L., Coma M., Rodriguez M., Sanchez-Ferrer P., Sanchez M.B., Gich I., Agullo J.M., Perez M., Avila J., Guardia-Laguarta C., Clarimon J., Lleo A., Gomez-Isla T. Anovel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss invivo. Neurobiol. Dis. 2009, 35:359-367.
50. Shi J.Q., Shen W., Chen J., Wang B.R., Zhong L.L., Zhu Y.W., Zhang Q.Q., Zhang Y.D., Xu J. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 2011, 1368:239-247.
51. Shin R.W., Ogino K., Shimabuku A., Taki T., Nakashima H., Ishihara T., Kitamoto T. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau. Acta Neuropathol. 2007, 113:627-636.
52. Simoes A.E., Pereira D.M., Amaral J.D., Nunes A.F., Gomes S.E., Rodrigues P.M., Lo A.C., D'Hooge R., Steer C.J., Thibodeau S.N., Borralho P.M., Rodrigues C.M. Efficient recovery of proteins from multiple source samples after TRIzol((R)) or TRIzol((R))LS RNA extraction and long-term storage. BMC Genomics 2013, 14:181.
53. Sola S., Amaral J.D., Borralho P.M., Ramalho R.M., Castro R.E., Aranha M.M., Steer C.J., Rodrigues C.M. Functional modulation of nuclear steroid receptors by tauroursodeoxycholic acid reduces amyloid beta-peptide-induced apoptosis. Mol. Endocrinol. 2006, 20:2292-2303.
54. Sola S., Castro R.E., Laires P.A., Steer C.J., Rodrigues C.M. Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol. Med. 2003, 9:226-234.
55. Soutar M.P., Kim W.Y., Williamson R., Peggie M., Hastie C.J., McLauchlan H., Snider W.D., Gordon-Weeks P.R., Sutherland C. Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. J.Neurochem. 2010, 115:974-983.
56. Tweedie D., Ferguson R.A., Fishman K., Frankola K.A., Van Praag H., Holloway H.W., Luo W., Li Y., Caracciolo L., Russo I., Barlati S., Ray B., Lahiri D.K., Bosetti F., Greig N.H., Rosi S. Tumor necrosis factor-alpha synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J.Neuroinflammation 2012, 9:106.
57. Viana R.J., Ramalho R.M., Nunes A.F., Steer C.J., Rodrigues C.M. Modulation of amyloid-beta peptide-induced toxicity through inhibition of JNK nuclear localization and caspase-2 activation. J.Alzheimers Dis. 2010, 22:557-568.
58. Wang M.J., Huang H.Y., Chen W.F., Chang H.F., Kuo J.S. Glycogen synthase kinase-3beta inactivation inhibits tumor necrosis factor-alpha production in microglia by modulating nuclear factor kappaB and MLK3/JNK signaling cascades. J.Neuroinflammation 2010, 7:99.
59. Webster S.J., Bachstetter A.D., Nelson P.T., Schmitt F.A., Van Eldik L.J. Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front. Genet. 2014, 5:88.
60. Wirths O., Bayer T.A. Neuron loss in transgenic mouse models of Alzheimer's disease. Int. J. Alzheimers Dis. 2010, 2010. pii: 723782.
61. Yang L.B., Lindholm K., Yan R., Citron M., Xia W., Yang X.L., Beach T., Sue L., Wong P., Price D., Li R., Shen Y. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 2003, 9:3-4.
62. Yanguas-Casas N., Barreda-Manso M.A., Nieto-Sampedro M., Romero-Ramirez L. Tauroursodeoxycholic acid reduces glial cell activation in an animal model of acute neuroinflammation. J.Neuroinflammation. 2014, 11:50.
63. Yuskaitis C.J., Jope R.S. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal. 2009, 21:264-273.
64. Zhu L.Q., Wang S.H., Liu D., Yin Y.Y., Tian Q., Wang X.C., Wang Q., Chen J.G., Wang J.Z. Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J.Neurosci. 2007, 27:12211-12220.